Gujarat Themis Biosyn Ltd
GUJTHEMGujarat Themis Biosyn Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 100th percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (14 weeks in) while the P/E sits at the 100th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +22.2% year on year, and 132% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Gujarat Themis Biosyn Ltd trades at ₹423, in a confirmed uptrend and 14 weeks into that stage. That is +14.9% against its own 200-day average. It sits at 81% of a 52-week range of ₹252 to ₹463. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹423 it trades +14.9% versus its 200-day average and sits at 81% of its 52-week range (₹252–₹463).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +5,507% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Gujarat Themis Biosyn Ltd trades at 113.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 50.7×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 113.0× is about the priciest it has ever traded, against a long-run median of 50.7× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −4.5% against a +11.9% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 10y, of the +51.6%/yr price move, ~+25.8%/yr came from earnings growth and ~+25.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Gujarat Themis Biosyn Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 4 quarters ago at −18.2% and has held its recovery at +6.7%, ROCE slipping at 18.5%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +9.9% | +3.9% | +12.8% | +17.5% |
| Profit | −4.1% | −6.8% | +9.4% | +25.1% |
| EPS | −4.5% | −7.0% | +9.1% | +26.1% |
| Share price | +11.9% | +58.0% | +48.7% | +51.6% |
4-Factor Sector Score
48.2/100 — rank 7 of 14 in Pharma - API · 93% evidence confidence
Gujarat Themis Biosyn Ltd scores 48.2 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.1 + 15.6 + 6.9 + 5.6 = 48.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Gujarat Themis Biosyn Ltd reported ₹44.0 Cr of revenue in the Jun 26 quarter, +22.2% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 17.5% a year. The last full year, FY26, came in at ₹166 Cr. The last four reported quarters add to ₹173 Cr.
FY26 revenue came in at ₹166 Cr (+9.9% on the year), capping 10 years at 17.5% compound. The latest quarter (Jun 26) printed ₹44.0 Cr, +22.2% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +16.4% growth against the decade's 17.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +16.1% over the last 4 quarters against +4.0%/yr over the last 8 — accelerating; TTM profit +6.7% vs −6.6%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Gujarat Themis Biosyn Ltd's operating margin is 48.0% in the Jun 26 quarter, +9.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 16.0% to 51.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 48.0%, +9.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 16.0%–51.0%.
Why the margin moved: operating margin went +8.7 pp year on year while gross margin went +9.2 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Gujarat Themis Biosyn Ltd earned ₹11.0 Cr of net profit in the Jun 26 quarter, +22.2% year on year. Full-year FY26 profit was ₹47.0 Cr. The 10-year compound rate is 25.1%. That is 25.0% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr.
Jun 26 profit was ₹11.0 Cr, +22.2% year on year. On the full year, FY26 printed ₹47.0 Cr (−4.1%), and the 10-year compound rate is 25.1%.
Why profit moved: revenue contributed +22.2% and the margin +9.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +8.4% vs revenue +16.4%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 132% of Gujarat Themis Biosyn Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹49.0 Cr of operating cash against ₹47.0 Cr of profit. After ₹198 Cr of capital spending, ₹−149 Cr was left as free cash.
FY26: operating cash of ₹49.0 Cr against reported profit of ₹47.0 Cr, leaving free cash of ₹−149 Cr after ₹198 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 132% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 132%: the cash cycle tightened 347 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 17.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Gujarat Themis Biosyn Ltd's cash conversion cycle runs −228 days in FY26, down from 119 days in FY21. Capital spending ran ₹378 Cr over the last 3 years. At FY26 sales of ₹166 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹−104 Cr sits inside the business at any moment.
FY26: debtors at 134 days, inventory at 263 days — roughly 8.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −228 days, tighter than FY21's 119.
The full loop: cash goes out to suppliers and production on day 0; stock waits 263 days to sell; customers pay about 134 days after that; and suppliers themselves are paid at 625 days — netting out to the −228-day cycle.
In money terms: at FY26 sales of ₹166 Cr, each day of the cycle holds about ₹0.5 Cr — so the −228-day loop keeps roughly ₹−104 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹378 Cr over the last 3 fiscal years against ₹22.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹121 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Gujarat Themis Biosyn Ltd earns a ROCE of 18% in FY26. Return on invested capital clears the cost of that capital by −0.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 28.3% net margin on 0.33× asset turns.
FY26 ROCE is 18%.
🚨 Why the return is what it is — the wiring (FY26): 28.3% net margin × 0.33× asset turns × 1.75× balance-sheet leverage ≈ 16.3% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 11.4% − 12.0% = a −0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Gujarat Themis Biosyn Ltd carries total debt of ₹162 Cr against shareholder equity of ₹288 Cr as of Mar 26, a debt-to-equity of 0.56. On the annual view that ratio went from 0.01 in FY22 to 0.56 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹162 Cr against shareholder equity of ₹288 Cr — a debt-to-equity of 0.56. On the annual view, debt-to-equity went from 0.01 (FY22) to 0.56 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 12.6 points of Gujarat Themis Biosyn Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 13.8% of the company. Promoters moved −11.5 points over the same window, to 59.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +12.6 points over 8 quarters to 13.8%; Promoters: −11.5 points over 8 quarters to 59.3%; Foreign institutions: +3.4 points over 8 quarters to 4.9%.
Why the register moved: domestic institutions drove it (+12.6 points), absorbed on the other side by promoters (−11.5 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Gujarat Themis Biosyn Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals LtdSENORES | 71.5/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 17.0/25 ROCE 15.1% · OPM 30% 76% evidence | 9.2/20 P/E 53.5× · PEG — 15% evidence | 12.9/20 RS sector 13.2% · RS bench 51.9% · 1Y 104%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 17 + 9.2 + 12.9 = 71.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 63.5/100Mixed-positive evidence81% evidence | ASLEEP | 19.9/35 Revenue 3.6% · PAT 30% · OPM change -5.2 pp 95% evidence | 18.6/25 ROCE 30.7% · OPM 9.8% 95% evidence | 14.3/20 P/E 14.1× · PEG — 50% evidence | 10.7/20 RS sector 5.3% · RS bench -4.7% · 1Y -14.5%5 of 11 weeks ahead 70% evidence |
| Exact sum: 19.9 + 18.6 + 14.3 + 10.7 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Innova Captab LtdINNOVACAP | 57.7/100Mixed-positive evidence100% evidence | LEADER | 24.8/35 Revenue 34.4% · PAT 18.5% · OPM change 1 pp 100% evidence | 13.2/25 ROCE 15% · OPM 16% 100% evidence | 5.9/20 P/E 42.6× · PEG 4.06 100% evidence | 13.8/20 RS sector 4.3% · RS bench 41.6% · 1Y 26.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 13.2 + 5.9 + 13.8 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ind-Swift Laboratories LtdINDSWFTLAB | 55.2/100Mixed-positive evidence87% evidence | LEADER | 23.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence | 6.0/25 ROCE 4.7% · OPM 17% 95% evidence | 6.1/20 P/E 51.5× · PEG — 50% evidence | 20.0/20 RS sector 88.3% · RS bench 147.7% · 1Y 277.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 6 + 6.1 + 20 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Anuh Pharma LtdANUHPHR | 53.1/100Mixed-positive evidence87% evidence | TURNING | 16.5/35 Revenue 9.7% · PAT -2.2% · OPM change 2 pp 95% evidence | 12.9/25 ROCE 14.9% · OPM 8% 95% evidence | 12.9/20 P/E 21.5× · PEG — 50% evidence | 10.8/20 RS sector -13% · RS bench 20.3% · 1Y 11.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.9 + 12.9 + 10.8 = 53.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 51.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.9/25 ROCE 22.7% · OPM 21% 95% evidence | 11.1/20 P/E 32.7× · PEG — 50% evidence | 5.4/20 RS sector -16.6% · RS bench 14.2% · 1Y -3.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 18.9 + 11.1 + 5.4 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Gujarat Themis Biosyn Ltdthis pageGUJTHEM | 48.2/100Mixed-negative evidence93% evidence | TURNING | 20.1/35 Revenue 16.1% · PAT 6.7% · OPM change 9 pp 100% evidence | 15.6/25 ROCE 14.8% · OPM 48% 100% evidence | 6.9/20 P/E 113× · PEG 2.55 65% evidence | 5.6/20 RS sector -16.4% · RS bench 15% · 1Y 10.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 15.6 + 6.9 + 5.6 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Aarti Drugs LtdAARTIDRUGS | 46.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.7/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 12.0/25 ROCE 12% · OPM 14% 100% evidence | 11.7/20 P/E 20.3× · PEG 2.4 100% evidence | 5.4/20 RS sector -22.6% · RS bench 6.9% · 1Y -9.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 12 + 11.7 + 5.4 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Fermenta Biotech LtdFERMENTA | 45.6/100Mixed-negative evidence74% evidence | BREAKING OUT | 5.0/35 Revenue -3.1% · PAT -44% · OPM change -5.9 pp 95% evidence | 14.3/25 ROCE 20.6% · OPM 14.8% 95% evidence | 10.8/20 P/E 25.5× · PEG — 15% evidence | 15.5/20 RS sector 15.7% · RS bench 38.2% · 1Y 42%9 of 9 weeks ahead 70% evidence |
| Exact sum: 5 + 14.3 + 10.8 + 15.5 = 45.6 · Decision use: Price leads the evidence: RS versus the benchmark is 38.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Beta Drugs LtdBETA | 45.0/100Mixed-negative evidence76% evidence | BREAKING OUT | 11.6/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.4/25 ROCE 19.2% · OPM 22% 76% evidence | 7.6/20 P/E 51.5× · PEG — 50% evidence | 7.4/20 RS sector -17.9% · RS bench 28% · 1Y 11.5%10 of 10 weeks ahead 70% evidence |
| Exact sum: 11.6 + 18.4 + 7.6 + 7.4 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Kopran LtdKOPRAN | 40.1/100Mixed-negative evidence81% evidence | TURNING | 14.5/35 Revenue 12% · PAT -28.4% · OPM change -0.2 pp 95% evidence | 9.6/25 ROCE 6.7% · OPM 10.3% 95% evidence | 7.1/20 P/E 45.5× · PEG — 50% evidence | 8.9/20 RS sector -17.6% · RS bench 46.7% · 1Y 32.9%10 of 11 weeks ahead 70% evidence |
| Exact sum: 14.5 + 9.6 + 7.1 + 8.9 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Orchid Pharma LtdORCHPHARMA | 36.9/100Mixed-negative evidence78% evidence | BREAKING OUT | 17.4/35 Revenue 14.1% · PAT -80% · OPM change 6.8 pp 74% evidence | 1.8/25 ROCE 1.7% · OPM 4.6% 100% evidence | 10.5/20 P/E 333× · PEG 1.77 65% evidence | 7.2/20 RS sector -19.8% · RS bench 30.5% · 1Y 40.7%11 of 11 weeks ahead 70% evidence |
| Exact sum: 17.4 + 1.8 + 10.5 + 7.2 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 33.8/100Adverse evidence94% evidence | BREAKING OUT | 10.2/35 Revenue 1.2% · PAT -20.2% · OPM change 1 pp 100% evidence | 11.8/25 ROCE 10.7% · OPM 25% 100% evidence | 3.4/20 P/E 34.8× · PEG 5.52 100% evidence | 8.4/20 RS sector -10.7% · RS bench 13.2% · 1Y -6.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 10.2 + 11.8 + 3.4 + 8.4 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Themis Medicare LtdTHEMISMED | 28.5/100Adverse evidence72% evidence | LEADER | 6.1/35 Revenue -12.9% · PAT 100% · OPM change -50 pp 71% evidence | 2.5/25 ROCE 2.7% · OPM -60% 95% evidence | 8.5/20 P/E 939.2× · PEG — 15% evidence | 11.4/20 RS sector -8.6% · RS bench 25.2% · 1Y 27.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 6.1 + 2.5 + 8.5 + 11.4 = 28.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Gujarat Themis Biosyn Ltd's share price today?
Gujarat Themis Biosyn Ltd trades at ₹423, +11.9% over the past year. The company is valued at ₹5,501 Cr. The stock sits at 81% of its 52-week range of ₹252–₹463, +14.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 11 September 2026.
What were Gujarat Themis Biosyn Ltd's latest quarterly results?
Gujarat Themis Biosyn Ltd reported revenue of ₹44.0 Cr and net profit of ₹11.0 Cr for the Jun 26 quarter. Revenue rose 22.2% and profit rose 22.2% year on year. Earnings per share were ₹1.02. The operating margin was 48.0%, 9.0 pp higher than a year earlier. — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's revenue?
Gujarat Themis Biosyn Ltd reported revenue of ₹44.0 Cr in the Jun 26 quarter, +22.2% year on year. For the full FY26 fiscal year, revenue was ₹166 Cr (+9.9%). Over the last 10 years revenue compounded at 17.5% a year. — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's profit?
Gujarat Themis Biosyn Ltd earned ₹11.0 Cr of net profit in the Jun 26 quarter, +22.2% year on year. Full-year FY26 profit was ₹47.0 Cr. The operating margin ran 48.0% in the latest quarter. — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's market cap?
Gujarat Themis Biosyn Ltd's market capitalisation is ₹5,501 Cr at a share price of ₹423. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's P/E ratio?
Gujarat Themis Biosyn Ltd trades at a P/E of 113.0×, at the most expensive it has been in 11 years, against a long-run median of 50.7×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Gujarat Themis Biosyn Ltd pay a dividend?
Not in its latest year — Gujarat Themis Biosyn Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 5 of its last 13 reported fiscal years, so there is a history but no current dividend. — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd overvalued?
On its own history, Gujarat Themis Biosyn Ltd looks expensive: its P/E of 113.0× sits at the most expensive it has been in 11 years (long-run median 50.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd growing?
Yes — Gujarat Themis Biosyn Ltd is growing: latest-quarter revenue +22.2% year on year, profit +22.2%, and the margin +9.0 pp at 48.0%. The 10-year compound rates are 17.5% (revenue) and 25.1% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Gujarat Themis Biosyn Ltd performing?
Gujarat Themis Biosyn Ltd is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 22.2% and profit rose 22.2% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Gujarat Themis Biosyn Ltd in?
Improving — profit growth bottomed 4 quarters ago at −18.2% and has held its recovery at +6.7%, ROCE slipping at 18.5%. The read comes from the last 12 quarters of growth (revenue growth +16.1% latest, profit growth +6.7% latest, eps growth +9.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +14.9% versus its 200-day average and at 81% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd beating the market?
On recent form, yes — Gujarat Themis Biosyn Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +5,507% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Gujarat Themis Biosyn Ltd's share price go up?
This page publishes no price forecast for Gujarat Themis Biosyn Ltd. What it measures instead: the share price is ₹423, the price is in a confirmed uptrend 14 weeks in. Its P/E of 113.0× sits at the 100th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Gujarat Themis Biosyn Ltd?
Promoters hold 59.3% of Gujarat Themis Biosyn Ltd, foreign institutions 4.9%, domestic institutions 13.8% and the public 21.9% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 12.6 points over 8 quarters. — as of 11 September 2026.
Does Gujarat Themis Biosyn Ltd have too much debt?
It is moderate — Gujarat Themis Biosyn Ltd's debt-to-equity is 0.56, and operating profit covers the interest bill 25×. FY26 borrowings were ₹162 Cr against equity of ₹288 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's capex?
Gujarat Themis Biosyn Ltd spent ₹378 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹198 Cr, with ₹121 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Gujarat Themis Biosyn Ltd's cash flow?
Gujarat Themis Biosyn Ltd generated ₹49.0 Cr of operating cash flow in FY26 and ₹−149 Cr of free cash flow after ₹198 Cr of capital spending. Reported profit that year was ₹47.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd's profit real cash?
Yes — over the last 3 fiscal years, 132% of Gujarat Themis Biosyn Ltd's reported profit arrived as operating cash. Though the latest year ran at 104% — the trend is the thing to watch. In FY26, operating cash was ₹49.0 Cr against reported profit of ₹47.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Gujarat Themis Biosyn Ltd in its business cycle?
Gujarat Themis Biosyn Ltd's FY26 operating margin was 46.0%, against a 13-year band of 16.0%–51.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 48.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Gujarat Themis Biosyn Ltd story?
The sharpest disagreement: the engine is strong, but at the 100th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Gujarat Themis Biosyn Ltd a stock worth studying right now?
This is not investment advice. The machine read: Gujarat Themis Biosyn Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!